Physician profile
Hal B Ganzman
NPI 1285794545
$3,401.88
in general payments reported to CMS, 2019-2025
20 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $440 · 2021: $611 · 2022: $530 · 2023: $408 · 2024: $568 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $861.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $526.25 | 2019-2024 | |
| Novo Nordisk INC | $383.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $251.56 | 2019-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.14 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $182.86 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $161.95 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $161.18 | 2020-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $141.53 | 2022-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.78 | 2019-2023 | Cycloset |
| Exact Sciences Corporation | $94.22 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $51.89 | 2019-2020 | |
| Abbvie INC. | $51.12 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $37.66 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $37.18 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.39 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $22.29 | 2024 | Repatha, Otezla |
| Bausch Health US, LLC | $22.21 | 2025 | Wellbutrin |
| Inspire Medical Systems, INC. | $18.76 | 2025 | Inspire |
| Intra-Sana Laboratories | $17.10 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Ganzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.